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HIV Pre-Exposure Prophylaxis: Are we “PrEPing” for a new epidemic?

I.

Introduction
On July 16, 2012, the FDA approved TRUVADA, the first drug approved to reduce the

risk of HIV infection in uninfected individuals who are at high risk of HIV infection, such as
those with an HIV-infected partner, or partners at high risk for HIV infection.1 Truvada for HIV
pre-exposure prophylaxis has been shown to prevent the spread of HIV.2 However, significant
risks exist if the drug recommendations are not properly adhered to which can lead to the spread
of the HIV virus, as well as other diseases.3 This paper will first discuss a brief history of HIV
medications and an introduction of how Pre=Exposure Prophylaxis (PrEP) was discovered, and
what PrEP is. The paper will further discuss the TRUVADA Risk Evaluation and Mitigation
Strategy (REMS) and the potential unintended consequences of the drug. The paper will then
conclude with the best course of action that should be followed to address these consequences.

Each new generation of doctors and scientists is faced with the challenge of new and
emerging diseases. These doctors and scientists join teams of established men and women who
have spent their lives tirelessly looking for discoveries to put an end to diseases that have taken
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the lives of many people. When a new drug is approved by the FDA and is shown to stop the
spread of the disease, prescribers and patients may jump at the chance to use the drug, especially
when they have lost all hope. Often, these prescribers and patients may utilize the treatments
before the full risks associated with the medication are appreciated.
II. Background
In 1981, doctors reported a new disease among homosexual men in the United States.4 It
would take four years before an antibody test was available to diagnose infection.5 In 1983, the
World Health Organization started Global HIV surveillance and held its first meeting on AIDS. 6
It would be years before the government took any action to acknowledge the AIDS crisis. 7
President Ronald Reagan did not mention AIDS publicly until 1986 and when he finally did utter
the word, he provided very limited funding.8 The significance of President Reagan’s delay in
speaking about AIDS is that his delay may have led to the dearth of knowledge about the disease
or what caused it, especially in groups at highest risk for infection, such as with men who have
sex with men (MSM).9 Without society having the education or knowledge of HIV and its
infectious potential, the disease spread and HIV infection rates soared. This remains relevant
today because we continue to inadequately educate people on the dangers of unprotected sex.

Advancement in the use of HIV medications has come a long way since the discovery of
the HIV virus. Azidothymidine, or AZT, was the first medication approved for the treatment of
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HIV infection, in the 1980s.10 Care of HIV infected patients improved markedly when additional
drugs were discovered, and the standard of care became use of several drugs in combination, a
concept known as Highly Active Anti-Retroviral Therapy (HAART).11 This concept remains the
cornerstone of HIV treatment today.12 In the subsequent years, physicians and scientists realized
that HIV medications were effective in preventing HIV infection in patients who had been
exposed to the virus.13 Post-Exposure Prophylaxis (PEP) for HIV was successful in preventing
HIV infections in healthcare workers exposed to the virus through needle sticks.14 AZT is still
the drug of choice for preventing perinatal HIV infection in the children of HIV-infected
pregnant patients15. AZT is administered to the mother in several doses around the time of
delivery, and is given to the newborn for the first 4-6 weeks of life. 16This is associated with an
HIV transmission rate near zero, whereas HIV perinatal transmission occurs about in 25% of
patients where there is no prophylaxis. 17 In recent years, HIV prevention guidelines
recommended the use of PEP in nonoccupational HIV exposures18. Nonoccupational PEP

10

Samuel Broder, The Development of antiretroviral therapy and its impact on the HIV-1/AIDS
pandemic, 85 Antiviral Research 1 (Jan. 2010).
11
Stefano M. Bertozzi, The Evolving HIV/AIDS Response And The Urgent Tasks Ahead, 28
Heath Affairs 1578-1590 (Nov. /Dec. 2009).
12
Id.
13
Id.
14
Id.
15
Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-1-Infected Women for
Maternal Health and Interventions to Reduce Perinatal HIV Transmission in the United States,
NIH.(Oct. 26, 2016).
http://www.aidsinfo.nih.gov/contentfiles/lvguidelines/peri_recommendations.pdf.
16
Id.
17
Id.
18
Updated Guideline for Antiretroviral Postexposure Prophylaxis After Sexual, Injection Drug
Use, or Other Nonoccupational Exposure to HIV-United States, 2016, CDC. (2016),
https://www.cdc.gov/hiv/pdf/programresources/cdc-hiv-npep-guidelines.pdf.
4

(nPEP) is highly effective when a three drug regimen is started within 72 hours after a high risk
exposure to the HIV virus, and continued for 28 days. 19
Antiretroviral drugs are one of the most lifesaving discoveries in recent medicine, having
saved millions of lives in patients infected with HIV, and have prevented countless potential
infections in exposed patients20. In 2012, a new frontier emerged in HIV prevention when an
existing HIV treatment was approved for use in HIV negative patients for the prevention of HIV
infection.21 Truvada is a brand-name medication containing two antiretroviral medications,
tenofovir and emtricitabine.22 Truvada was initially approved for the treatment of HIV infection
in 2004 in combination with other medications.23 It is also a component of three drug regimens
for HIV post exposure prophylaxis.24 Approval of Truvada for a pre-exposure prophylaxis is
indeed life changing, and in some cases lifesaving, but it is vitally important that a greater effort
be made to ensure that the drug is used safely.25 Modifications to how the drug is prescribed
must be made to ensure that the drug is used safely and that patients are receiving the maximum
benefit of the drug without the acquisition of unnecessary or unappreciated risk. 26

In 1987 the FDA approved the drug zidovudine (AZT).27 AZT was the first drug
available to treat HIV but it had significant obstacles in the treatment of the HIV infection.28 The
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cost of the medication was extremely expensive and the medication had major toxicity.29 Even
with the high costs and burden of side effects, the drug did not have a long survival benefit that
outweighed the obstacles.30
Next, there was a development of a multi-drug therapy that was discovered to work better
than AZT and this was considered one of the great success stories of modern medicine.31 It was
discovered that the virus mutates and that a combination of drugs together would more
effectively fight the disease.32 This combination of drugs (HAART) changed what was once a
nearly universally fatal illness to a manageable chronic disease.33
TRUVADA was first approved by the FDA in August of 2004 as a safe and effective
treatment for HIV.34 It was then discovered that individuals who take antiviral therapy shortly
after exposure to HIV have a strong likelihood of avoiding infection.35 This is known as PEP
(post-exposure prophylaxis), and if taken within 72 hours of exposure is highly effective.36
PrEP (Pre-exposure prophylaxis) was discovered based on the observation of monitoring
how PEP worked.37 PEP is prescribed when someone is or believes that they are exposed to the
HIV virus.38 The crucial aspect of the efficacy of PEP is the time from HIV exposure to the first
dose of antiretroviral medication.39 The time between when someone was exposed to HIV and
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the time they took PEP was essential in getting the maximum benefit of the drug.40 The closer
the timeframe from exposure to medication approaches zero, the better chance the person has of
not contracting the disease.41

PrEP is a means of using medications to prevent HIV infection in uninfected patients.42
On July 16, 2012, the FDA approved a new indication for TRUVADA.43 It was now the first
drug approved to reduce the risk of HIV infection in uninfected individuals who are at high risk
of HIV infection and who may engage in sexual activity with HIV-infected partners.44 The
approval of TRUVADA was postponed a month because of pressing ethical concerns with the
drug.45 First, there was a concern that TRUVADA could encourage riskier behavior and
potentially lead to higher rates of the HIV infection.46 Second, non-adherence to the strict dosing
rules can lead to more virulent strains of the virus.47 Questions remain about whether the
potential for non-adherence could cause more harm than the drug does good.48
III. Truvada REMS
To address these serious ethical issues surrounding approval of TRUVADA for PrEP, the
FDA required Gilead, the manufacturer of TRUVADA, to provide a risk evaluation and
mitigation strategy (REMS).49 REMS provides important information about adherence and the
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risk of developing drug resistance.50 However, the REMS may not adequately address unrealistic
expectations on the part of patients. 51
The Food and Drug Administration Amendments Act (FDAAA) clarified FDA’s
authority to require enforceable risk management programs such as REMS.52 Section 505-1 of
the FDAAA states when the FDA may require a REMS: “1) before approval: If the FDA
determines a REMS is necessary to ensure that the benefits of the drug outweigh the risks. 2)
Post approval: if the FDA becomes aware of new safety information and determining if REMS is
necessary to ensure the benefits of the drug outweigh the risk.”53 An applicant is also permitted
to voluntarily submit a proposed REMS if they believe it is necessary. 54There are many factors
that the FDA must consider when determining the need for a REMS. They must consider, “1) the
size of the population that is likely to use the drug. 2)the seriousness of the disease; 3) the
expected benefit of the drug; 4) the expected duration of the treatment; 5) the seriousness of
known or potential adverse events and 6) whether the drug is a new molecular entity.”55

The FDA determined that a REMS is necessary to ensure that the benefits of TRUVADA
outweigh whatever risks it may impose.56 PrEP was approved with a risk evaluation and
mitigation strategy (REMS) to minimize the risk to uninfected individuals of acquiring HIV
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infection and to reduce the risk of development of resistant HIV-1 variants.57 The core
component of the TRUVADA REMS is a training and educational program to assist prescribers
in counseling individuals who are taking or considering TRUVADA for PrEP.58 The goals of
the REMS for TRUVADA as a PrEP indication are:
To inform and educate prescribers and uninfected
individuals at high risk for acquiring HIV-1 infection about: the
importance of strict adherence to the recommended dosing
regimen. The importance of regular monitoring of HIV-1
serostatus to avoid continuing to take TRUVADA for a PrEP
indication, if seroconversion has occurred, to reduce the risk of
development of resistant HIV-1 variants. The fact that TRUVADA
for a PrEP indication must be considered as only a part of a
comprehensive prevention strategy in order to reduce the risk of
HIV-1 infection and that other preventive measures should also be
used.59

The first and most important goal of the REMS is to inform patients of the critical need
for strict adherence to the recommended dosing regimen.60 Patients must be instructed that daily
dosing must be maintained or the patient will not receive the maximum benefits of the drug.61
The second goal is to ensure that patients are continuously being re-tested to make sure that they
continue to test negative.
The importance of regular monitoring of HIV-1 serostatus to
avoid continuing to take TRUVADA for a PrEP indication, if
seroconversion has occurred, to reduce the risk of development of
resistant HIV-1 variants. “A negative HIV-1 test must be
confirmed immediately before starting TRUVADA for a PrEP.
indication and reconfirmed during treatment. Drug resistant HIV-1
variants have been identified with the use of TRUVADA for a
PrEP indication following uninfected HIV-1 infection.62
57
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It is important to note that monotherapy with TRUVADA is only adequate for preexposure prophylaxis in an HIV uninfected patient.63 The two drugs in Truvada, when taken
alone, are not effective for the treatment of HIV.64 Current standards recommend a three-drug
regimen for HIV treatment.65 Using fewer than three drugs for the treatment of HIV has been
shown to lead to inadequate suppression of the virus and has been associated with the
development of drug-resistant strains of HIV.66 Since the drugs contained in Truvada are also
core components in many regimens for HIV treatment, drug resistance to one or both of these
medications would significantly limit the treatment options available to a newly infected
patient.67 It is essential that a patient know their HIV status during the entire duration of
treatment with PrEP for HIV prevention.68 If the patient ever has a confirmed positive result,
they must discontinue PrEP and begin treatment for the disease.69
The REMS for Truvada consists of a training guide for healthcare providers which has
prescribing considerations such as,
Only prescribe TRUVADA as a comprehensive prevention
strategy…counsel all uninfected individuals to strictly adhere to
their TRUVADA daily dosing schedule…confirm a negative HIV1 test immediately prior to initiating TRUVADA for a PrEP
indication…screen uninfected individuals for HIV-1 infection at
least one every 3 months…do not prescribe TRUVADA for PrEP
indication if signs or symptoms of acute HIV infection are
present.70
63
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There is also a safety guide for patients.71 The guide informs patients that they should
make sure that they are HIV negative and stay negative while on PrEP.72 One section of the
guide reads “Just taking Truvada alone may not keep you from getting HIV-1 infection…You
must continue using safer sex practices while you are taking TRUVADA to reduce your risk of
getting HIV-1 infection.” 73 Interestingly, the word “condom” does not appear anywhere in this
safety guide. It is making the assumption that 1) Patients will actually read this guide, and 2)
That patients that do read the guide are capable to understand that condoms are being implied by
the phrase “using safer sex practices.”74

IV. Barriers to Access
There are barriers to accessing PrEP that can create obstacles to patients who may benefit
from the drug.75 The first major barrier is that people who can benefit from the drug are not
receiving it because they may not even know that it exists.76 Accessibility is a barrier to PrEP
because it is a prescription only medication, and obtaining it requires a patient-provider
discussion about patients’ sexual behaviors and level of risk.77 Those who may know it exists
may not feel comfortable discussing their sexual activity in front of doctors.78 “In a recent survey
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of over 9,000 MSM in the US, 16% did not have a primary care provider and only half of those
with a provider felt comfortable talking to them about sex.”79 If patients do not have a primary
doctor that they see on a regular basis then they are less likely to feel comfortable to confide in a
perfect stranger.80 Patients in greatest need of PrEP may feel uncomfortable to discuss sexuality,
let alone discuss their homosexuality and specific sexual behaviors which may place them at
highest risk. 81
Other patients may avoid getting PrEP because there is a stigma in regards to any type of
HIV medication.82 PrEP may be associated with the stigma because people may believe that
PrEP users are HIV infected.83 There is a stigma that if someone is using PrEP they are
promiscuous or irresponsible.84 There are cultural and moral beliefs that someone that is using
any type of HIV drug either has HIV or they are at high risk of being infected.85 Furthermore,
“Prep may have generated ‘moral panic’ in certain stakeholders concerned about a potential loss
of sexual restraints, leading to so-called risk compensation (i.e. having riskier sex and thereby
neutralizing the benefit of prep).86 Even with the gay community, this concern has created a
certain stigma affecting prep.”87
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Another issue of concern for MSM patients is the stigma of receptive sex.88 There is a
stigma that men who are the receptive partner are feminine and often these individuals may be
reluctant to be honest about their sexual role out of shame or embarrassment.89 This is critically
relevant to HIV prevention, because the risk of being infected with HIV is substantially higher
for the receptive partner in MSM relationships.90 Being an insertive partner is ten times less
risky than being a receptive partner.91 There is a 1 in 500 chance of becoming infected from one
incident of unprotected anal sex with an HIV positive receptive partner, but there is a 1 in 50
chance of becoming infected from one incident of unprotected anal sex with an HIV positive
insertive partner.92 Since men who engage in receptive sex are more at risk of contracting HIV,
they should be the first to take advantage of PrEP.93 Yet, this group of MSM may be less likely
to ask their doctor about the drug for fear of being judged for their preferred sexual position.94
About 14% of the more than 1.2 million Americans living with HIV are unaware of their
status.95 For young people the numbers are more troubling.96 More than half of HIV-infected
people age 13 to 24 are unaware of their status.97 The large number of cases that are
undiagnosed or diagnosed at, an advanced state, represent lost opportunity for prevention and
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treatment.98 Over time, however, it became clear that stigma and discrimination, which deter
people from getting tested and seeking treatment were significant barriers to an effective public
health response.99 In 2001 the United Nations called on states to enact law to eliminate all forms
of discrimination against, and to ensure the full enjoyment of all human rights and fundamental
freedoms by people living with HIV/AIDS and members of vulnerable group.100
Destigmatization has the dual purpose of safeguarding individual rights and protecting the
public’s health by reducing transmission.101

Provider-level barriers include a lack of PrEP awareness and knowledge.102 Often,
patients go to their primary care doctor for advice on medical conditions or to seek treatment for
an unknown illness.103 Unfortunately, most generalists, even in urban areas with high HIV
prevalence, are the least uninformed about the availability and use of PrEP.104 HIV specialists
have the most experience and knowledge about PrEP but often patients do not seek out an HIV
specialist.105 There may be a stigma that if an individual seeks out an HIV specialist that people
will think that they have HIV.106 They will avoid these specialists who have the most knowledge
about the medication and who would be better educated at discussing the requirements of

98
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receiving the maximum benefit from the drug.107 Furthermore, those patients who are unfamiliar
with PrEP would not know to seek out a specialist, even if they were motivated to do so.108
A survey was developed to evaluate the current practices and attitudes among infectious
disease experts. 109 The main purpose of this survey was to access provider opinions, readiness
and current practices of PrEP in the United States and Canada.110 Questions included the
physician’s HIV practice, whom they provided or would provide PrEP to, how they assess
eligibility, how they measure adherence, when they would discontinue PrEP, and what perceived
barriers exist.111. Nearly 75% of those physicians that responded supported the provision of PrEP
but only 9% of those physicians actually provided PrEP to patients.112 Most physicians stated
that they did not provide PrEP because they were worried about adherence and the risk for future
resistance. 113 There was a concern from these doctors that there was a lack of resources and
information and that they don’t know enough to feel comfortable enough to prescribe the
medication.114 When doctors were asked to rank the order of barriers to prescribing PrEP, many
stated that it was too time consuming to counsel and access adherence.115
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Another barrier to access is financial coverage for the medication.116 The high cost of the
medication can pose a significant hardship on the individual and some may even think the cost is
not worthwhile.117 The issue with this barrier is, even when patients have prescription coverage
for the medication, navigating the requirements to get approval for the medication is time
consuming.118 It is often difficult to get approval and this can be very discouraging for many
patients.119 There is a paradox where uninsured patients could access PrEP through patient
assistance programs but patients who are insured do not have access to the program because only
uninsured qualify.120 Though these patients may have medical insurance, they cannot afford the
medication because of the high cost of the deductible.121 There is also a concern that because
follow-ups and monitoring are required they won’t be able to afford the frequent co-pays for the
doctor visits, testing and refills.122 Financial constraints could also be a barrier to implanting
PrEP in government funded or subsidized health systems.123
V. Adherence Concerns
Another issue is that some people who are receiving PrEP are not using it correctly.124
There is a strong concern about adherence.125 Adherence was strong among patients who
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actively sought PrEP.126 These patients researched what PrEP was and how it could change their
lives or they knew of friends or family who told them about the drug and its benefits.127 Many
patients cite condom use as a barrier to physical intimacy and sexual pleasure.128 Patients who
sought out PrEP on their own initiative were more likely to diligently use condoms and were
motivated to seek a suitable alternative were much more responsible in adhering to the
requirements of treatment.129 Alternatively, patients who started prophylaxis at the
recommendation of their doctors tended to be less adherent.130 In fact, some of these patients
were overwhelmed by the follow-ups that were required and often did not return.131

Adherence among one of the target demographics for PrEP, young MSM, was most
concerning.132 Most patients under the age of 25 have a limited degree of routine; they often do
not do the same thing every day.133 This particular demographic is specifically unfamiliar with a
daily regimen of medications accompanied by relatively frequent doctor visits.

134

Another barrier is the anticipated behavior (risk compensation).
This concern is best explained by the prevailing theory
about how individuals manage their personal risks. Risk
“homeostasis” is defined as “a system in which individuals accept
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their health in exchange for benefits they expect to receive from an
activity” In accepting a particular level of risk for an adverse event,
individuals maintain an approximate risk set point. However,
introduction of an intervention that reduces the perceived risk of
126
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the behavior or activity may cause a person to increase risky
behavior- this is called “risk compensation” so that the discrepancy
between the level of risk he or she takes and the perceived risk
increases.135
In a study regarding ART (formally known as HAART), it was found that people who
believed ART reduced the likelihood of HIV transmission or “lessened the likelihood of
transmission were more likely to engage in unprotected sex.”136 With this information it would
seem plausible that people would have the same feelings about PrEP.137 Prior to the FDA
approval of PrEP, potential users were surveyed and reported that they believed taking PrEP
could decrease their use of condoms.138 But risk compensation after PrEP implementation has
been examined in several trials and to date has not been associated with increased sexual risk
behavior or sexually transmitted infections in the majority of these studies.139 However, this may
not be true in clinical practice; “all randomized and open-label trials of PrEP have provided and
emphasized the use of condoms, as well as HIV testing: this model may not be fully
implemented in clinical practice…sexual risk behaviors have been shown to increase following
significant HIV biomedical breakthroughs.”140
There is a misconception that PrEP is all that is needed to prevent the HIV virus when
engaged in sexual activity.141 In a recent study on the use of PrEP, 30% of men reported that
they would not use condoms or they would use condoms less often if they were on PrEP.142 One

135

Jill Blumenthal & Richard Haubrect, Risk compensation in PrEP: An old debate emerges yet
again. 16 AMA Journal of Ethics (Nov. 2014).
136
Id.
137
Id.
138
Id.
139
Id.
140
Id.
141
Colleen C. Hoff, PhD, Attitudes Towards PrEP and Anticipated Condom Use Among
Discordant Male Couples, 29 Aids Patient Care and STDs 408 (June 9, 2015).
142
Id.
18

MSM in the study said, “If I were using it, I would assume I wouldn’t have to use a condom.”143
The use of condoms is essential in combination with the drug to receive the highest level of the
benefit of the medication.144 Though PrEP may help decrease the spread of the HIV infection, it
does not stop the spread of other sexually transmitted diseases The CDC reported,
Trend data shows the rate of syphilis are increasing at an alarming
rate (15.1 percent in 2014). While rates have increased among both
men and women, men account for more than 90 percent of all
primary and secondary syphilis cases. Men who have sex with men
(MSM) account for 83 percent of male cases where the sex of the
partner is known. Primary and secondary syphilis are the most
infections stages of the disease, and if not adequately treated, can
lead to long-term infection which can cause visual impairment and
stroke.145
One reason that has been given to why sexually transmitted diseases is on the rise is
because the change in behavior among gay and bisexual men and it correlates with the advent of
HIV treatment.146 PrEP has changed what people think of HIV. Individual outlooks on the
disease have changed considerably, but maybe to their detriment.147 Dr. Gail Bolan from the
CDC was interviewed by NBC news and stated, “People are excited about it, and some have
stopped using condoms so consistently, because they are no longer afraid of a deadly
infection.148 But, unfortunately, HIV treatment has no impact on prevention of other STDs.
unless you are using condoms consistently and correctly, you are putting yourself at risk for
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STDs.”149 The 2015 CDC fact sheet shows that since 2014 Chlamydia is up 6%, Gonorrhea is up
13%, Syphilis (primary and secondary) is up 19% and congenital syphilis is up 6%.150
Even though adherence to the strict dosing is essential, condom use must still be adhered
to. The problem lies with patients who believe as long as they adhere to the dosing requirements
they do not need to use condoms.
Initial data from demonstration studies in MSM show that
people who choose to take PrEP may, in fact, be those who report
episodes of unprotected anal intercourse, and their reported PrEP
adherence is already high, with no subsequent risk compensation
of change from their present condom use. Hence, at least among
MSM, PrEP may become a choice among people at risk due to
condomless anal sex, who feel that a daily pill may suit them better
than condoms.151
The presumption that condoms are unnecessary while taking PrEP is critically flawed.152
Pre-exposure prophylaxis with TRUVADA alone does not confer 100% protection from HIV
infection.153 It is essential that condoms are used in combination with the medication. “PrEP was
misunderstood as intended to replace condoms, while in fact it was meant to become one element
(but never the sole element) of the emerging paradigm of combination prevention.154
David Knox, MD recently reported a case study at the 2016 Conference on Retroviruses
and Opportunistic Infections (CROI) of a 43-year-old MSM with excellent adherence to the
medication who tested positive for HIV after 2 years of treatment with PrEP.155 The patient’s
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adherence was confirmed with pharmacy dispensing records, as well as blood tests for levels of
the medication.156 Despite this excellent adherence and adequate drug levels in the body, he still
contracted the HIV infection.157 This was the first reported case of HIV infection with evidence
of long-term adherence to PrEP, but it would not be only case.158 In October of 2016, researchers
at the 2016 HIV research for Prevention Conference made an announcement that a second man
in the Unites States acquired HIV despite that he also was using PrEP.159 Dr. Howard Grossman,
a New York City Physician, says that the man is his patient and was adhering to the PrEP dosing
requirements since 2015.160 Dr. Grossman stated in an interview that “the man had required a
rare strain of HIV that is resistant to both of the drugs found in TRUVADA.”161 Dr. Knox’s
patient similarly acquired a strain of HIV resistant to both medications in TRUVADA.162
Drug resistance is a particular concern if a patient is not consistently tested every three
months.163 There is a concern that if a person continues to take PrEP when they are already
infected, resistance to the medication may develop, “the box warning for tenofovir-emtricitabine,
includes cautionary language regarding the need to ensure that those using the product for prep
are HIV-uninfected before initiating use and they are regularly tested.”164 The current labeling
for TRUVADA does not have a warning label in regards to adherence or using safer sex
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practices.165 Without clear and simple instructions on how to take their medicines, these patients
are subjected to medication errors that may lead to poor adherence and sub-therapeutic
outcomes.166 Complexity of written information hinders patients’ understanding of their
medications which then leads to misuse of prescribed medications.167
One way to enhance patient understanding would be to develop patient warning labels.
Prescription warning labels (PWLs) are small, colorful stickers adjacent to the prescription label
on dispensing bottles that remind or highlight the most important instructions for patient’s safe
and effective use of medications.168 For example, PWL’s contain warning statements about
specified medications such as “do not take with alcohol: or “take with food.”169 Including the
word “WARNING” creates alertness. Patients expressed that the word “WARNING” drew their
attention to the PWL and it made them think of the cautionary instruction.170 Similar, pictorial
warning labels were suggested on cigarette packs to convince people that smoking was bad for
their health.171 Requiring pictorial warning labels on all cigarette packs would be appropriate
for the protection of the public health because it would substantially reduce smoking prevalence
and thereby reduce SADs and the morbidity and medical costs associated with adverse smokingattributable birth outcomes.172 In 2009, the Family Smoking Prevention and Tobacco Control Act
was signed into law, authorizing the FDA to regulate cigarettes and other tobacco products,
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including their packaging and labeling. 173 The D.C. Circuit Court of Appeals struck down the
rule and hinged in part on a concern that the pictorial warning labels might not produce any
significant reduction in smoking. 174 With recent studies on the effect of PWLS on prescription
drugs there should be more of a warning on TRUVADA bottles and packaging.

Another barrier is that young people are engaging in sexual activity at a much younger
age and are often not educated on proper safer practices.
According to the Center for Disease Control, almost half of U.S.
high schoolers (46 percent) have had sexual intercourse, with
approximately 6 percent having an age of sexual initiation as
young as 13 years old. That means for the first few years a person
is at the highest risk for acquiring HIV, they aren’t eligible for
Truvada Prep per the FDA approval…we see that these are also the
groups with the greatest risk factors for non-adherence.175
The most important risk of this medication is that some MSMs will continue to believe
that PrEP is all that is needed to not get infected with HIV.176 Numerous casual dating sites such
as Manhunt, ADAM4ADAM and phone applications like GRINDR that make casual sex easier
than ever.177 Looking through these sites, one quickly finds an enormity of profiles that in search
of condomless sex: “bareback only – HIV negative on PREP.”178 These profiles make the
mistaken claim that bareback (unprotected) sex is safe, provided one party is on PrEP. 179 These
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individuals are mistakenly reassured in their immunity to HIV, not to mention their heightened
risk for other sexually transmitted infections.180 This is a problem that may see astronomical
destruction, especially among the gay population. 181
According to the study, Zero feet away Perspective on HIV/AIDS and unprotected sex in
men who have sex with men utilizing location based mobile Apps, a total 727 participants were
recruited through advertisements placed on large geo-social networking apps for MSM
responded to questionnaires about unprotected sex182. Nearly 50 % of the men surveyed said they
are afraid of getting infected or re-infected with the virus, yet they persist to participate in risky
taking activities such as unprotected anal intercourse. An astounding 46 % admitted to never
using condoms. 183

There are also concerns that the medication has some potential side effects which may
cause patients to stop taking the medication as prescribed.184 Toxicity is a problem associated
with the medication.185 The medication, in a small number of patients, has caused kidney and
liver issues. “PrEP can cause decreases in kidney and liver function and bone mineral density,
promisingly, renal function tended to return to normal after discontinuation of PrEP.”186 The
problem with this is that the medication has to be stopped in order for the renal function to
normalize but PrEP has a strict dosing requirement; it is not meant to be discontinued.187
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V. Possible Solutions

Education for both the provider, as well as the patient is key is to addressing some of the
potential barriers. Provider-level barriers include a lack of PrEP awareness and knowledge, as
well as negative opinions and attitudes toward PrEP. 188 The first step is to increase the
awareness and knowledge of the benefits of PrEP among at risk populations and service
providers.189 Adherence is critical to reduce HIV infections.190
If the public is not educated, there will be another epidemic that can sweep in. The
Syphilis outbreak in the 1930’s was a huge epidemic that was fueled by stigma surrounding
testing and a concern that treatment would increase sexual risk behaviors.191 Practitioners need to
make sure that patients seeking PrEP are not stigmatized in the same way that patients in the
1930’s were stigmatized regarding syphilis.192

There needs to be formal training and educational seminars so that prescribers are fully
trained in effectively treating at risk patients about the use of PrEP. Currently, there is no formal
training for prescribers or patients.193 “Nearly all providers indicated that they were self-educated
with respect to PrEP. Rather than participating in formal training, their knowledge about PrEP
was obtained through a combination of reading relevant literature, attending professional talks
and conferences, consulting with colleagues.”194
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The New York State Department of Health Aids Institute produced a Guidance of PreExposure Prophylaxis to Prevent HIV Transmission on what appropriate protocols should be
followed to receive the maximum benefits of PrEP.195 They suggest to first screen the patient to
ensure they are a candidate for the medication196. Next is to educate patient on how PrEP works,
including its risks and benefits197. They emphasize that strict adherence is needed to maintain
protective drug levels.198 Next, it is imperative that a negative test result is confirmed before
PrEP is prescribed.199 The guidelines then suggest that once PrEP is prescribed to have the
patient follow up in two weeks to assess possible side effects200. Then the patient should visit
every three months for another HIV test to make sure that the patient is still testing negative and
also assess kidney function and screen for other STIs. It is very important that there is follow-up
management and monitoring. Prescribers should not only test the patient every three months for
HIV infection and other STIs, but should also discuss prevention services such as risk reduction
counseling and access to condoms.201
Before HIV was discovered, in the 1970’s and 1980’s gay men had a sexual freedom to
do what they wanted, where they wanted and with whomever they wanted. Sex was happening in
a variety of different places.
Establishments including certain bars, clubs and bathhouses
which are used as places for engaging in high risk sexual activities
contribute to the propagation and spread of such AIDS-associated
retro-virus; Appropriate public health interventions to discontinue
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such exposure at such establishments is essential to interrupting the
epidemic among the people of the State of New York. 202

Bathhouses were closed down due to the public health concern of widespread HIV
infection at these establishments.203 This lead to the spread of the virus because men would meet
up at these establishments and have unprotected sex because they were not aware of the
consequences204. With PrEP, again MSM are not aware of the consequences.205 There is a new
sexual liberation among gay men who believe that they can do what they want without protection
and there are no consequences to having unprotected sex.206 In the 1970’s no one knew what
HIV was, what AIDS was.207 No one knew that there was this horrendous disease that would kill
millions of people.208 In 2015 there were 17 million people living with HIV who were on
antiretroviral therapy.209 There were 2.1 million new HIV infections. In 2014 there were 390,000
Tuberculosis-related AIDS deaths. In 2015 there were 36.7 million people worldwide living with
HIV. there were 1.1million AIDS related deaths.210 Since the beginning of the epidemic, 78
million people have contracted HIV and 35 million have died of AIDS-related causes. 211
Without condom use there is a chance of individuals contracting HIV and any of the many other
sexually transmitted diseases that can cause death.
Deaths from sexually transmitted diseases (STDs) often
occur long after acute infection, making their incidence difficult to
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estimate. Some infections, such as syphilis, may directly result in
death. By contrast, human papilloma virus (HPV), HIV, and
hepatitis more commonly cause death because of secondary
sequelae. Genital herpes, gonorrheal infection, and chlamydial
infection may cause death from primary infection. 212

The safety guidelines part of the REMS need to be modified.213 There is not one place in
the REMS guidelines where the word condom appears.214 The guidelines should be clearer and
say, “You must still use condoms while on this medication.” If people are fully aware that they
must still use condoms with this medication, some might choose to forgo the medication and just
use condoms.215
The REMS are merely suggestions. 216The REMS say “Uninfected individuals SHOULD
be counseled about safer sex practices…SHOULD be tested to confirm they are HIV-1
negative…SHOULD be screened at least every 3 months for HIV-1 status.”217 These guidelines
only use the word “should,” it is a suggestion, meaning that they are able to deter from this
guideline. These guidelines should be a “must.” If prescribers are able to deter from these
guidelines, then patients and prescribers need to know what the consequences are if they do not
adhere to these recommendations. HIV testing is mandatory in the United States for blood and
organ donors, military applicants and sometimes federal and state prisons.218
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HIV- testing should be mandatory for anyone that is being prescribed PrEP. Testing
should continue to be mandatory on a regular basis to make sure they are continuously being
monitored to ensure they are not taking the medication while already have the virus. Perhaps
there should be some type of mandatory computer system or registry to verify and confirm
repeated testing results. New York State currently uses this type of system for prescription
monitoring program for certain controlled substances.219 Prescribers are required to consult the
prescription monitoring program, known as I-Stop when prescribing controlled substances to
determine whether prescription have been obtained elsewhere.220 Prescribers of PrEP could have
a similar system where they must consult with a registry to make sure that when prescribing
PrEP initial or as a refill, a patient is being retested for HIV.
Another possible solution is more research is needed to see why adherence is such a
problem and how to decrease the stigma in associated with PrEP. Destigmatization is very
important in order for patients to feel more comfortable is seeking out the drug. In 2001 the
United Nations called on states to enact law to eliminate all forms of discrimination against, and
to ensure the full enjoyment of all human rights and fundamental freedoms by people living with
HIV/AIDS and members of vulnerable group. 221
In spite of being described as a miracle, employing the drug Truvada as PrEP remains a
highly contested and often stigmatized solution for prevention.222 Studying messages about PrEP
on Twitter is valuable because it allows for a unique opportunity to explore how individuals
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discussed PrEP.223 This is helpful to health professionals interested in understanding how to
better address PrEP related stigma and how to reduce barriers to PrEP adoption.224 Stigmas and
barriers to PrEP over the course of the history of AIDS in the US, significant portion of the
American population reported feeling anger, disgust, fear, and blame toward people with
AIDS.225 HIV-related stigmatization continues to occur because of the implication that PrEP will
encourage people to abandon the safer sex practices, some MSM who take it report they were
stigmatized by their medical provides, friends and sex partners.226 Huffington Post columnist
David Duran referred to gay0 men on PrEP as “Truvada whores” because they might engage in
condomless intercourse.227 In a widely cited Associated Press article, the President of the AIDS
Healthcare foundation, Michael Weinstein described PrEP as a party drug.228

VI. Conclusion.

Randomized placebo-controlled studies have demonstrated that daily oral anti-retroviral
pre-exposure chemoprophylaxis (PrEP) can significantly reduce HIV incidence among diverse
at-risk populations.229 In these studies, the efficacy of PrEP was correlated with levels of
adherence.230 These challenges include low awareness and utilization of PrEP by high risks
persons, uncertainty about the drug. However, several potential barriers to implementing PrEP
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remain. These include low awareness and utilization of PrEP by at-risk persons, uncertainty
about adherence in real world settings, the majority of healthcare providers being untrained in
PrEP provision, limited data about potential adverse effects from long-term use of tenofaviremtricitabine, high costs of PrEP medication and stigma. 231

PrEP has not been around long enough to fully appreciate the long term effects. There is
not enough research to show that a person can use this drug for an extended period of time
safely. There are concerns that PrEP may lead to more opportunities for drug resistant strains of
HIV to develop. 232 New diseases are discovered all the time. 50 years ago AIDS did not exist
and when it was discovered, it would be years before testing could be done and even longer for
treatment. If patients do not adhere to the recommendations to use PrEP properly with the
combination of condoms, then we may face another public health epidemic with a new disease
that may be transmitted sexually.
Not everyone is educated on the use of PrEP. Not only do the patients that are being
prescribed need the education but also their sexual partners. If a person tells his partner that he is
on PrEP, there is no indication or proof that he has been taking the recommended dose or that he
is continuing to be tested for HIV as the guidelines recommend. The public needs to to know
what to ask and they need to be educated about the consequences of non-adherence.
Education was an important element in fighting the spread of AIDS. Today there is a lack
of education, and media coverage is almost non existent about HIV and AIDS. There needs to be
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constant training and education on AIDS and HIV and the use of treatment therapies and
prevention.
If society continues to disregard the requirements to use PrEP with condoms, then society
will face another epidemic when a new deadly disease is discovered and history will
unfortunately repeat itself. PrEP is a miracle drug that has saved lives and changed how the
world thinks about HIV. There needs to be modifications to how the medicine is prescribed and
there needs to be better education and information about adherence to the drug.
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